Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Gastric Cancer

Free Subscription Articles published in Br J Cancer Retrieve available abstracts of 29 articles: HTML format

Single Articles

May 2025
1. LEE KW, Zang DY, Kim HD, Kim JW, et al
   Multicenter phase Ib/II study of second-line durvalumab and tremelimumab in combination with paclitaxel in patients with biomarker-selected metastatic gastric cancer.
   Br J Cancer. 2025 May 21. doi: 10.1038/s41416-025-03052.
   PubMed     Abstract available
   
   
   
2. GROEN-VAN SCHOOTEN TS, Cabeza-Segura M, Ferreira RM, Martinez-Ciarpaglini C, et al
   Immune profiling of gastric adenocarcinomas in EU and LATAM countries identifies global differences in immune subgroups and microbiome influence.
   Br J Cancer. 2025;132:783-792.
   PubMed     Abstract available
   
   
   April 2025
3. SUN M, Gu Y, Wang J, Zhang Z, et al
   Smad4 loss identifies aggressive subtype with immunotherapy and anti-HER-2 treatment resistance in gastric cancer.
   Br J Cancer. 2025 Apr 25. doi: 10.1038/s41416-025-03002.
   PubMed     Abstract available
   
   
   
4. LI J, Tao M, Liu L, Liu C, et al
   Peripheral blood neutrophils contribute to Claudin18.2-specific CAR-T cell treatment resistance in advanced gastric cancer.
   Br J Cancer. 2025 Apr 17. doi: 10.1038/s41416-025-03015.
   PubMed     Abstract available
   
   
   
5. LU J, Chen Y, Liu X, Wang J, et al
   Artificial intelligence-driven microRNA signature for early detection of gastric cancer: discovery and clinical functional exploration.
   Br J Cancer. 2025 Apr 15. doi: 10.1038/s41416-025-02984.
   PubMed     Abstract available
   
   
   March 2025
6. TSUTSUMI C, Ohuchida K, Yamada Y, Shimada Y, et al
   Claudin18.2-positive gastric cancer-specific changes in neoadjuvant chemotherapy-driven immunosuppressive tumor microenvironment.
   Br J Cancer. 2025 Mar 24. doi: 10.1038/s41416-025-02981.
   PubMed     Abstract available
   
   
   September 2024
7. CHEN C, Han J, He Q, Yao Q, et al
   Tumor-infiltrating immune cell profiles and changes associate with additional trastuzumab in preoperative chemotherapy for patients with HER2-positive gastric cancer.
   Br J Cancer. 2024 Sep 23. doi: 10.1038/s41416-024-02835.
   PubMed     Abstract available
   
   
   
8. KANDA M, Kasahara Y, Shimizu D, Shinozuka T, et al
   Dual-modified antisense oligonucleotides targeting oncogenic protocadherin to treat gastric cancer.
   Br J Cancer. 2024 Sep 20. doi: 10.1038/s41416-024-02859.
   PubMed     Abstract available
   
   
   August 2024
9. GU Y, Sun M, Fang H, Shao F, et al
   Impact of clonal TP53 mutations with loss of heterozygosity on adjuvant chemotherapy and immunotherapy in gastric cancer.
   Br J Cancer. 2024 Aug 31. doi: 10.1038/s41416-024-02825.
   PubMed     Abstract available
   
   
   July 2024
10. FANG M, Lin Y, Xue C, Sheng K, et al
    The AKT inhibitor AZD5363 elicits synthetic lethality in ARID1A-deficient gastric cancer cells via induction of pyroptosis.
    Br J Cancer. 2024 Jul 13. doi: 10.1038/s41416-024-02778.
    PubMed     Abstract available
    
    
    
11. HARA Y, Baba Y, Oda E, Harada K, et al
    Presence of Fusobacterium nucleatum in relation to patient survival and an acidic environment in oesophagogastric junction and gastric cancers.
    Br J Cancer. 2024 Jul 12. doi: 10.1038/s41416-024-02753.
    PubMed     Abstract available
    
    
    
12. ANGERILLI V, Sabella G, Simbolo M, Lagano V, et al
    Comprehensive genomic and transcriptomic characterization of high-grade gastro-entero-pancreatic neoplasms.
    Br J Cancer. 2024;131:159-170.
    PubMed     Abstract available
    
    
    June 2024
13. LI X, Xie G, Chen J, Wang Y, et al
    Tumour cell-derived serglycin promotes IL-8 secretion of CAFs in gastric cancer.
    Br J Cancer. 2024 Jun 11. doi: 10.1038/s41416-024-02735.
    PubMed     Abstract available
    
    
    May 2024
14. MURPHY JD, Gadalla SM, Anderson LA, Rabkin CS, et al
    Autoimmune conditions and gastric cancer risk in a population-based study in the United Kingdom.
    Br J Cancer. 2024 May 22. doi: 10.1038/s41416-024-02714.
    PubMed     Abstract available
    
    
    March 2024
15. SUH YS, Lee J, George J, Seol D, et al
    RNA expression of 6 genes from metastatic mucosal gastric cancer serves as the global prognostic marker for gastric cancer with functional validation.
    Br J Cancer. 2024 Mar 11. doi: 10.1038/s41416-024-02642.
    PubMed     Abstract available
    
    
    February 2024
16. SAITO T, Kurokawa Y, Fujitani K, Kawabata R, et al
    Serum NY-ESO-1 antibody as a predictive biomarker for postoperative recurrence of gastric cancer: a multicenter prospective observational study.
    Br J Cancer. 2024 Feb 7. doi: 10.1038/s41416-023-02540.
    PubMed     Abstract available
    
    
    
17. CECCHINI M, Cleary JM, Shyr Y, Chao J, et al
    NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma.
    Br J Cancer. 2024;130:476-482.
    PubMed     Abstract available
    
    
    
18. GROSSER B, Emmerson J, Reitsam NG, Cunningham D, et al
    Stroma AReactive Invasion Front Areas (SARIFA) improves prognostic risk stratification of perioperative chemotherapy treated oesophagogastric cancer patients from the MAGIC and the ST03 trial.
    Br J Cancer. 2024;130:457-466.
    PubMed     Abstract available
    
    
    January 2024
19. WANG J, Sun N, Kunzke T, Shen J, et al
    Metabolic heterogeneity affects trastuzumab response and survival in HER2-positive advanced gastric cancer.
    Br J Cancer. 2024 Jan 24. doi: 10.1038/s41416-023-02559.
    PubMed     Abstract available
    
    
    
20. CAI F, Yang X, Ma G, Wang P, et al
    EGLN3 attenuates gastric cancer cell malignant characteristics by inhibiting JMJD8/NF-kappaB signalling activation independent of hydroxylase activity.
    Br J Cancer. 2024 Jan 6. doi: 10.1038/s41416-023-02546.
    PubMed     Abstract available
    
    
    December 2023
21. KAMIYA H, Komatsu S, Takashima Y, Ishida R, et al
    Low blood level of tumour suppressor miR-5193 as a target of immunotherapy to PD-L1 in gastric cancer.
    Br J Cancer. 2023 Dec 26. doi: 10.1038/s41416-023-02532.
    PubMed     Abstract available
    
    
    November 2023
22. ALLAN Z, Witts S, Tie J, Tebbutt N, et al
    The prognostic impact of peritoneal tumour DNA in gastrointestinal and gynaecological malignancies: a systematic review.
    Br J Cancer. 2023;129:1717-1726.
    PubMed     Abstract available
    
    
    August 2023
23. CHEN T, Li D, Wang Y, Shen X, et al
    Loss of NDUFS1 promotes gastric cancer progression by activating the mitochondrial ROS-HIF1alpha-FBLN5 signaling pathway.
    Br J Cancer. 2023 Aug 29. doi: 10.1038/s41416-023-02409.
    PubMed     Abstract available
    
    
    
24. ANDO K, Nakamura Y, Kitao H, Shimokawa M, et al
    Mutational spectrum of TP53 gene correlates with nivolumab treatment efficacy in advanced gastric cancer (TP53MUT study).
    Br J Cancer. 2023 Aug 2. doi: 10.1038/s41416-023-02378.
    PubMed     Abstract available
    
    
    July 2023
25. LIU X, Lv K, Wang J, Lin C, et al
    C-type lectin receptor Dectin-1 blockade on tumour-associated macrophages improves anti-PD-1 efficacy in gastric cancer.
    Br J Cancer. 2023 Jul 8. doi: 10.1038/s41416-023-02336.
    PubMed     Abstract available
    
    
    
26. LEE JE, Kim KT, Shin SJ, Cheong JH, et al
    Genomic and evolutionary characteristics of metastatic gastric cancer by routes.
    Br J Cancer. 2023 Jul 8. doi: 10.1038/s41416-023-02338.
    PubMed     Abstract available
    
    
    June 2023
27. DONG X, Fan J, Xie W, Wu X, et al
    Efficacy evaluation of chimeric antigen receptor-modified human peritoneal macrophages in the treatment of gastric cancer.
    Br J Cancer. 2023 Jun 29. doi: 10.1038/s41416-023-02319.
    PubMed     Abstract available
    
    
    April 2023
28. LIU DHW, Kim YW, Sefcovicova N, Laye JP, et al
    Tumour infiltrating lymphocytes and survival after adjuvant chemotherapy in patients with gastric cancer: post-hoc analysis of the CLASSIC trial.
    Br J Cancer. 2023 Apr 7. doi: 10.1038/s41416-023-02257.
    PubMed     Abstract available
    
    
    
29. LAAKSONEN MA, Li S, Canfell K, MacInnis RJ, et al
    The future burden of oesophageal and stomach cancers attributable to modifiable behaviours in Australia: a pooled cohort study.
    Br J Cancer. 2023;128:1052-1069.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Gastric Cancer is free of charge.